Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[(sec-butylphen)AuCl3] is a neutral, distorted square pyramidal gold(III) coordination complex featuring a 2-sec-butyl-1,10-phenanthroline ligand. Developed as a potential metallotherapeutic alternative to cisplatin, the compound demonstrates significant in vitro cytotoxicity against various tumor cell lines, including lung and head and neck cancers, often surpassing the potency of cisplatin. While it exhibits enhanced stability against biological reductants like glutathione compared to other gold(III) complexes, its in vivo efficacy in xenograft models has been limited, likely due to high binding affinity for serum albumin proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [(sec-butylphen)AuCl3].